2. >>Products

Beximco Delivers First Cut-Price Generic Paxlovid

 
• By Anju Ghangurde

Bangladesh’s Beximco signed off 2021 on a high launching the first generic version of Pfizer’s Paxlovid at about $186 for a five-day treatment course and claimed that it has ‘adequate capacities' for exports as well.

accelerate
Beximco launches first generic Paxlovid • Source: Alamy

Within days of the US Food and Drug Administration’s emergency use authorization for Pfizer’s Paxlovid (nirmatrelvir and ritonavir tablets, co-packaged for oral use), Bangladesh’s Beximco Pharmaceuticals announced that it had rolled out the first cut-price generic of the oral pill for the treatment of mild-to-moderate COVID-19.

Rabbur Reza, Beximco Pharmaceuticals' chief operating officer, told Generics Bulletin sister publication Scrip that the company had developed the product (available as Bexovid) “on its own [based on

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.